Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. The company is engaged in the development of prescription drugs designed to treat rare neuromuscular and neurological diseases. The company’s lead product candidate is designed to treat Lambert-Eaton Myasthenic Syndrome (LEMS).